A nanodrug incorporating siRNA PD-L1 and Birinapant for enhancing tumor immunotherapy. (29th October 2021)

• Record Type: Journal Article
• Authors: Gong, Tingting; Cai, Yujun; Sun, Fengze; Chen, Jiaxin; Su, Zhongzhen; Shuai, Xintao; Shan, Hong
• Is Part Of: Biomaterials science. Volume 9:Number 23(2021)
• Page Start: 8007
• Page End: 8018
• Publication Date: 2021-10-29
• Subjects: Biomedical materials -- Periodicals; 610.28
• DOI: 10.1039/d1bm01299a
• Languages: English
• ISSNs: 2047-4830

Abstract

Abstract : Triple-negative breast cancer (TNBC) is associated with a worse prognosis and higher mortality than other breast cancers, and intensive effort has been made to develop therapies targeting TNBC. Abstract : Triple-negative breast cancer (TNBC) is associated with a worse prognosis and higher mortality than other breast cancers, and intensive effort has been made to develop therapies targeting TNBC. TNBC shows higher expression levels of programmed cell death ligand 1 (PD-L1) than other breast cancer types, which leads to a decrease in the killing effects of CD8 + T cells in the tumor microenvironment. Inhibitors of apoptosis proteins (IAPs) could prevent cell death through suppressing caspase activity. Here, Birinapant, an antagonist of IAPs, was found to promote the tumor infiltration of CD8 + T cells via increasing the secretion of the chemokine CXCL9. In addition, Birinapant could inhibit tumor growth via increasing the secretion of and the sensitivity to TNF-α in a TNBC xenotransplantation mouse model. Consequently, liposomes encapsulating Birinapant and siPD-L1 mediated a form of combination therapy based on two drugs to significantly increase the therapeutic effects toward TNBC.